Articles

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia

Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Department of Leukemia, The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA
Vol. 100 No. 5 (2015): May, 2015 https://doi.org/10.3324/haematol.2014.118588